On May 9, 2024, Gilead Sciences, Inc announced that it held its annual general meeting of shareholders on May 8, 2024, and declared voting results. Accordingly, a shareholder proposal from Bowyer Research, Inc. on behalf of David Bahnsen, requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks was not approved.